ClinicalTrials.gg
CompletedNCT04588480Updated Feb 1, 2023Results posted

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

A Phase 4 interventional study of BNT162b2 and Placebo in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 2 sites in Japan. Open to participants aged 20 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-01.

Sponsored by BioNTech SE · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
41st of 54
160 · median 575
Started
2020
with 4 others
Phase 4
11 of 54
2 open now
Registered
4th of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 41st largest by enrollment, is one of 5 that started in 2020, is one of 11 in phase 4, and was the 4th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

This is a Phase 1/2, randomized, placebo-controlled, and observer-blind study in healthy Japanese adults.

The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19:

  • As 2 doses, separated by 21 days
  • At a single dose level
  • In adults 20 to 85 years of age
Read the detailed description

From protocol amendment 3, this study is transitioned from a clinical trial to a postmarketing study (Phase 4) according to the Japanese regulation, because BNT162b2 was approved by the Ministry of Health, Labour and Welfare on 14 February 2021.

03

Conditions studied

  • SARS-CoV-2 Infection
  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese male or female participants between the ages of 20 and 85 years, inclusive, at randomization.
  • Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Capable of giving personal signed .

Exclusion criteria

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Known infection with (HIV), virus (HCV), or virus (HBV).
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
  • Receipt of medications intended to prevent COVID-19.
  • Previous confirmed diagnosis of COVID-19.
  • individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Previous vaccination with any coronavirus vaccine.
  • Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic , eg, for cancer or an disease, or planned receipt throughout the study.
  • Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.
  • Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
  • Previous participation in other studies involving study intervention containing lipid nanoparticles.
  • Subset only: Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality.
  • Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    BNT162b2

    BNT162b2 (intramuscular injection)

    Biological: BNT162b2

  • Placebo comparator
    Placebo

    Placebo (intramuscular injection)

    Other: Placebo

Interventions

  • BiologicalBNT162b2

    BNT162b2 (intramuscular injection)

  • OtherPlacebo

    Placebo (intramuscular injection)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1

    Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.

    Time frame: Within 7 days after Dose 1

  2. Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 2

    Local reactions included pain at injection site, redness and swelling and were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: \> 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.

    Time frame: Within 7 days after Dose 2

  3. Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 1

    Systemic events were recorded by participants in e-diary. Fever was categorized as greater than or equal to (\>=)37.5 to 38.4 degrees(deg) Celsius(C), \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.

    Time frame: Within 7 days after Dose 1

  4. Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 2

    Systemic events were recorded by participants in an e-diary. Fever was categorized as \>= 37.5 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.

    Time frame: Within 7 days after Dose 2

  5. Percentage of Participants With Adverse Events (AEs) From Dose 1 up to 1 Month After Dose 2

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 95% confidence interval (CI) based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Dose 1 up to 1 month after Dose 2

  6. Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 up to 12 Months After Dose 2

    SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or considered an important medical event. Percentage of participants with SAEs and the associated 95% CI based on the Clopper and Pearson method was presented.

    Time frame: Dose 1 up to 12 months after Dose 2

  7. Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 1 Day After Dose 1 by Age Category

    The pre-defined criteria for laboratory parameters included: hemoglobin (HGB), hematocrit, erythrocytes(ery.) less than (\<)0.8\* lower limit of normal (LLN); ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*upper limit of normal (ULN); platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.

    Time frame: Within 1 day after Dose 1

  8. Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 1 by Age Category

    The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \<0.8\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*ULN; platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.

    Time frame: Within 7 days after Dose 1

  9. Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 2 by Age Category

    The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \<0.8\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*ULN; platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Categories with at least 1 non-zero data value were reported (only 65-85 years: Lymphocytes category was reported).

    Time frame: Within 7 days after Dose 2

  10. Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 1 Day After Dose 1 by Age Category

    Hematology parameters: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, white blood cell (WBC) decrease, WBC increase. Chemistry parameters: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, blood urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in Grade from baseline to 1 day after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.

    Time frame: From baseline (observation prior to Dose 1) up to 1 day after Dose 1

  11. Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 7 Days After Dose 1 by Age Category

    Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from baseline to 7 days after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.

    Time frame: From baseline (observation prior to Dose 1) up to 7 days after Dose 1

  12. Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Before Dose 2 to 7 Days After Dose 2 by Age Category

    Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3= severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from before dose 2 to 7 days after dose 2 were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.

    Time frame: Before Dose 2 up to 7 days after Dose 2

  13. Geometric Mean Titers (GMTs) of SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 2

    GMT of SARS-CoV-2 neutralizing titer was calculated by exponentiating the mean logarithm of the titers and the corresponding 95% confidence interval (CI) was based on the Student's t distribution. GMT of SARS-CoV-2 neutralization titer 50% (NT50) was reported in this outcome measure.

    Time frame: 1 month after Dose 2

  14. Geometric Mean Fold Rises (GMFRs) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After Dose 2

    GMFR was defined as the result after vaccination divided by the result before vaccination. GMFR and the corresponding 2-sided 95% CIs was calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFR of SARS-CoV-2 NT50 was reported in this outcome measure.

    Time frame: Before vaccination up to 1 month after Dose 2

Secondary outcomes

  1. GMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2

    GMTs of SARS-CoV-2 neutralizing titers were calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution. GMTs of SARS-CoV-2 NT50 and neutralization titer 90% (NT90) were reported in this outcome measure.

    Time frame: NT50: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days after Dose 2

  2. GMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2

    GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFRs of SARS-CoV-2 NT50 and NT90 were reported in this outcome measure.

    Time frame: NT50: Before vaccination up to 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2

  3. GMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2

    GMTs of SARS-CoV-2 neutralizing titers was planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution.

    Time frame: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 1, 6 and 12 months after Dose 2

  4. GMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2

    GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution).

    Time frame: Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2 and 1, 6 and 12 months after Dose 2

07

Results

Posted Feb 1, 2023

Participant flow

Blinded Phase: Up to 6 Months
Participant flow — Blinded Phase: Up to 6 Months
MilestoneBNT162b2PlaceboPlacebo Then BNT162b2
Started119410
Completed119410
Not completed000
Unblinded Phase: From 6 to 12 Months
Participant flow — Unblinded Phase: From 6 to 12 Months
MilestoneBNT162b2PlaceboPlacebo Then BNT162b2
Started119635
Completed117335
Not completed230
Withdrew: Protocol violation010
Withdrew: Other220

Outcome measures

PrimaryPercentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1

Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1
Percentage of participantsBNT162b2Placebo
Redness: Mild7.6 (3.5 to 13.9)0.0 (0.0 to 8.6)
Redness: Moderate5.9 (2.4 to 11.7)0.0 (0.0 to 8.6)
Redness: Severe0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Redness: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Swelling: Mild9.2 (4.7 to 15.9)0.0 (0.0 to 8.6)
Swelling: Moderate3.4 (0.9 to 8.4)0.0 (0.0 to 8.6)
Swelling: Severe0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Swelling: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Pain at the injection site: Mild57.1 (47.7 to 66.2)2.4 (0.1 to 12.9)
Pain at the injection site: Moderate27.7 (19.9 to 36.7)0.0 (0.0 to 8.6)
Pain at the injection site: Severe1.7 (0.2 to 5.9)0.0 (0.0 to 8.6)
Pain at the injection site: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
PrimaryPercentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 2

Local reactions included pain at injection site, redness and swelling and were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: \> 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 2
Percentage of participantsBNT162b2Placebo
Redness: Mild6.0 (2.5 to 12.0)0.0 (0.0 to 8.6)
Redness: Moderate4.3 (1.4 to 9.8)0.0 (0.0 to 8.6)
Redness: Severe0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Redness: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Swelling: Mild4.3 (1.4 to 9.8)0.0 (0.0 to 8.6)
Swelling: Moderate4.3 (1.4 to 9.8)0.0 (0.0 to 8.6)
Swelling: Severe0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Swelling: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Pain at the injection site: Mild50.9 (41.4 to 60.3)0.0 (0.0 to 8.6)
Pain at the injection site: Moderate26.7 (18.9 to 35.7)0.0 (0.0 to 8.6)
Pain at the injection site: Severe1.7 (0.2 to 6.1)0.0 (0.0 to 8.6)
Pain at the injection site: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
PrimaryPercentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 1

Systemic events were recorded by participants in e-diary. Fever was categorized as greater than or equal to (\>=)37.5 to 38.4 degrees(deg) Celsius(C), \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 1
Percentage of participantsBNT162b2Placebo
Fever: >= 37.5 to 38.4 deg C11.8 (6.6 to 19.0)0.0 (0.0 to 8.6)
Fever: >38.4 to 38.9 deg C2.5 (0.5 to 7.2)0.0 (0.0 to 8.6)
Fever: >38.9 to 40.0 deg C0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Fever: >40.0 deg C0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Fatigue: Mild22.7 (15.5 to 31.3)7.3 (1.5 to 19.9)
Fatigue: Moderate16.8 (10.6 to 24.8)2.4 (0.1 to 12.9)
Fatigue: Severe0.8 (0.0 to 4.6)0.0 (0.0 to 8.6)
Fatigue: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Headache: Mild21.8 (14.8 to 30.4)7.3 (1.5 to 19.9)
Headache: Moderate10.1 (5.3 to 17.0)7.3 (1.5 to 19.9)
Headache: Severe0.8 (0.0 to 4.6)0.0 (0.0 to 8.6)
Headache: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Chills: Mild16.0 (9.9 to 23.8)4.9 (0.6 to 16.5)
Chills: Moderate8.4 (4.1 to 14.9)0.0 (0.0 to 8.6)
Chills: Severe0.8 (0.0 to 4.6)0.0 (0.0 to 8.6)
Chills: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Vomiting: Mild0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Vomiting: Moderate0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Vomiting: Severe0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Vomiting: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Diarrhea: Mild3.4 (0.9 to 8.4)0.0 (0.0 to 8.6)
Diarrhea: Moderate1.7 (0.2 to 5.9)0.0 (0.0 to 8.6)
Diarrhea: Severe0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Diarrhea: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
New or worsened muscle pain: Mild10.1 (5.3 to 17.0)2.4 (0.1 to 12.9)
New or worsened muscle pain: Moderate4.2 (1.4 to 9.5)0.0 (0.0 to 8.6)
New or worsened muscle pain: Severe0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
New or worsened muscle pain: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
New or worsened joint pain: Mild9.2 (4.7 to 15.9)4.9 (0.6 to 16.5)
New or worsened joint pain: Moderate4.2 (1.4 to 9.5)0.0 (0.0 to 8.6)
New or worsened joint pain: Severe0.8 (0.0 to 4.6)0.0 (0.0 to 8.6)
New or worsened joint pain: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
PrimaryPercentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 2

Systemic events were recorded by participants in an e-diary. Fever was categorized as \>= 37.5 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 2
Percentage of participantsBNT162b2Placebo
Fever: >= 37.5 to 38.4 deg C25.0 (17.4 to 33.9)0.0 (0.0 to 8.6)
Fever: >38.4 to 38.9 deg C6.9 (3.0 to 13.1)0.0 (0.0 to 8.6)
Fever: >38.9 to 40.0 deg C0.9 (0.0 to 4.7)0.0 (0.0 to 8.6)
Fever: >40.0 deg C0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Fatigue: Mild25.9 (18.2 to 34.8)2.4 (0.1 to 12.9)
Fatigue: Moderate31.0 (22.8 to 40.3)0.0 (0.0 to 8.6)
Fatigue: Severe3.4 (0.9 to 8.6)0.0 (0.0 to 8.6)
Fatigue: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Headache: Mild25.0 (17.4 to 33.9)7.3 (1.5 to 19.9)
Headache: Moderate17.2 (10.9 to 25.4)4.9 (0.6 to 16.5)
Headache: Severe1.7 (0.2 to 6.1)0.0 (0.0 to 8.6)
Headache: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Chills: Mild24.1 (16.7 to 33.0)2.4 (0.1 to 12.9)
Chills: Moderate19.8 (13.0 to 28.3)0.0 (0.0 to 8.6)
Chills: Severe1.7 (0.2 to 6.1)0.0 (0.0 to 8.6)
Chills: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Vomiting: Mild0.9 (0.0 to 4.7)0.0 (0.0 to 8.6)
Vomiting: Moderate0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Vomiting: Severe0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Vomiting: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Diarrhea: Mild5.2 (1.9 to 10.9)0.0 (0.0 to 8.6)
Diarrhea: Moderate0.0 (0.0 to 3.1)2.4 (0.1 to 12.9)
Diarrhea: Severe0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
Diarrhea: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
New or worsened muscle pain: Mild9.5 (4.8 to 16.3)0.0 (0.0 to 8.6)
New or worsened muscle pain: Moderate6.9 (3.0 to 13.1)0.0 (0.0 to 8.6)
New or worsened muscle pain: Severe0.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
New or worsened muscle pain: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
New or worsened joint pain: Mild12.9 (7.4 to 20.4)0.0 (0.0 to 8.6)
New or worsened joint pain: Moderate11.2 (6.1 to 18.4)0.0 (0.0 to 8.6)
New or worsened joint pain: Severe0.9 (0.0 to 4.7)0.0 (0.0 to 8.6)
New or worsened joint pain: Grade 40.0 (0.0 to 3.1)0.0 (0.0 to 8.6)
PrimaryPercentage of Participants With Adverse Events (AEs) From Dose 1 up to 1 Month After Dose 2

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 95% confidence interval (CI) based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Dose 1 up to 1 month after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) From Dose 1 up to 1 Month After Dose 2
Percentage of participantsBNT162b2Placebo
Percentage of Participants With Adverse Events (AEs) From Dose 1 up to 1 Month After Dose 210.9 (5.9 to 18.0)7.3 (1.5 to 19.9)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) From Dose 1 up to 12 Months After Dose 2

SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or considered an important medical event. Percentage of participants with SAEs and the associated 95% CI based on the Clopper and Pearson method was presented.

Time frame:
Dose 1 up to 12 months after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 up to 12 Months After Dose 2
Percentage of participantsBNT162b2Placebo
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 up to 12 Months After Dose 21.7 (0.2 to 5.9)0 (0.0 to 8.6)
PrimaryPercentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 1 Day After Dose 1 by Age Category

The pre-defined criteria for laboratory parameters included: hemoglobin (HGB), hematocrit, erythrocytes(ery.) less than (\<)0.8\* lower limit of normal (LLN); ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*upper limit of normal (ULN); platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.

Time frame:
Within 1 day after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 1 Day After Dose 1 by Age Category
Percentage of participantsBNT162b2Placebo
20-64 Years: Monocytes11.10.0
65-85 Years: Lymphocytes22.20.0
65-85 Years: Monocytes11.10.0
65-85 Years: Creatinine11.10.0
PrimaryPercentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 1 by Age Category

The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \<0.8\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*ULN; platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 1 by Age Category
Percentage of participantsBNT162b2Placebo
20-64 Years: Eosinophils11.10.0
65-85 Years: Lymphocytes0.033.3
PrimaryPercentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 2 by Age Category

The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \<0.8\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*ULN; platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Categories with at least 1 non-zero data value were reported (only 65-85 years: Lymphocytes category was reported).

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 2 by Age Category
Percentage of participantsBNT162b2Placebo
Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 2 by Age Category22.233.3
PrimaryPercentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 1 Day After Dose 1 by Age Category

Hematology parameters: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, white blood cell (WBC) decrease, WBC increase. Chemistry parameters: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, blood urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in Grade from baseline to 1 day after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.

Time frame:
From baseline (observation prior to Dose 1) up to 1 day after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 1 Day After Dose 1 by Age Category
Percentage of participantsBNT162b2Placebo
20-64 Years- Lymphocytes: Normal (at baseline) to Grade 1 (at post baseline)22.20.0
20-64 Years- Neutrophil Decrease: Normal (at baseline) to Grade 1 (at post baseline)55.60.0
20-64 Years- WBC Decrease: Normal (at baseline) to Grade 1 (at post baseline)11.10.0
65-85 Years- Alanine Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline)11.10.0
65-85 Years-Aspartate Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline)11.10.0
65-85 Years- Hemoglobin: Normal (at baseline) to Grade 1 (at post baseline)11.133.3
65-85 Years- Lymphocytes: Normal (at baseline) to Grade 1 (at post baseline)33.30.0
65-85 Years- Neutrophil Decrease: Normal (at baseline) to Grade 1 (at post baseline)22.20.0
65-85 Years- Neutrophil Decrease: Normal (at baseline) to Grade 2 (at post baseline)11.10.0
65-85 Years- Urea Nitrogen: Normal (at baseline) to Grade 1 (at post baseline)0.033.3
65-85 Years- WBC Decrease: Normal (at baseline) to Grade 1 (at post baseline)33.30.0
PrimaryPercentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 7 Days After Dose 1 by Age Category

Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from baseline to 7 days after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.

Time frame:
From baseline (observation prior to Dose 1) up to 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 7 Days After Dose 1 by Age Category
Percentage of participantsBNT162b2Placebo
20-64 Years- Hemoglobin: Normal (at baseline) to Grade 1 (at post baseline)11.10.0
20-64 Years- Neutrophil Decrease: Grade 1 (at baseline) to Normal (at post baseline)11.10.0
65-85 Years- Alanine Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline)11.10.0
65-85 Years-Aspartate Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline)11.10.0
65-85 Years- Hemoglobin: Normal (at baseline) to Grade 1 (at post baseline)11.133.3
65-85 Years- Hemoglobin: Grade 1 (at baseline) to Grade 2 (at post baseline)11.10.0
65-85 Years- Lymphocytes: Normal (at baseline) to Grade 1 (at post baseline)0.033.3
65-85 Years- WBC Decrease: Normal (at baseline) to Grade 1 (at post baseline)0.033.3
PrimaryPercentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Before Dose 2 to 7 Days After Dose 2 by Age Category

Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3= severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from before dose 2 to 7 days after dose 2 were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.

Time frame:
Before Dose 2 up to 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Before Dose 2 to 7 Days After Dose 2 by Age Category
Percentage of participantsBNT162b2Placebo
20-64 Years- Alanine Aminotransferase Increased: Grade 1 (before dose 2) to Normal (post dose 2)11.10.0
20-64 Years- Eosinophils: Grade 1 (before dose 2) to Normal (post dose 2)11.10.0
20-64 Years- Hemoglobin: Normal (before dose 2) to Grade 1 (post dose 2)11.10.0
20-64 Years- Hemoglobin: Grade 1 (before dose 2) to Normal (post dose 2)11.133.3
20-64 Years- Neutrophil Decrease: Grade 1 (before dose 2) to Normal (post dose 2)22.20.0
20-64 Years- WBC Decrease: Grade 1 (before dose 2) to Normal (post dose 2)11.10.0
65-85 Years-Aspartate Aminotransferase Increased: Normal (before dose 2) to Grade 1 (post dose 2)11.10.0
65-85 Years- Bilirubin: Grade 1 (before dose 2) to Normal (post dose 2)11.10.0
65-85 Years- Hemoglobin: Normal (before dose 2) to Grade 1 (post dose 2)11.10.0
65-85 Years- Hemoglobin: Grade 1 (before dose 2) to Grade 2 (post dose 2)11.10.0
65-85 Years- Lymphocytes: Normal (before dose 2) to Grade 1 (post dose 2)0.033.3
65-85 Years- Neutrophil Decrease: Normal (before dose 2) to Grade 1 (post dose 2)22.233.3
65-85 Years- Urea Nitrogen: Normal (before dose 2) to Grade 1 (post dose 2)0.033.3
65-85 Years- WBC Decrease: Normal (before dose 2) to Grade 1 (post dose 2)11.133.3
PrimaryGeometric Mean Titers (GMTs) of SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 2

GMT of SARS-CoV-2 neutralizing titer was calculated by exponentiating the mean logarithm of the titers and the corresponding 95% confidence interval (CI) was based on the Student's t distribution. GMT of SARS-CoV-2 neutralization titer 50% (NT50) was reported in this outcome measure.

Time frame:
1 month after Dose 2
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 2
TiterBNT162b2Placebo
Geometric Mean Titers (GMTs) of SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 2524.5 (459.7 to 598.4)10.6 (9.8 to 11.4)
PrimaryGeometric Mean Fold Rises (GMFRs) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After Dose 2

GMFR was defined as the result after vaccination divided by the result before vaccination. GMFR and the corresponding 2-sided 95% CIs was calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFR of SARS-CoV-2 NT50 was reported in this outcome measure.

Time frame:
Before vaccination up to 1 month after Dose 2
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rises (GMFRs) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After Dose 2
Fold riseBNT162b2Placebo
Geometric Mean Fold Rises (GMFRs) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After Dose 251.5 (45.2 to 58.7)1.1 (1.0 to 1.1)
SecondaryGMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2

GMTs of SARS-CoV-2 neutralizing titers were calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution. GMTs of SARS-CoV-2 NT50 and neutralization titer 90% (NT90) were reported in this outcome measure.

Time frame:
NT50: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days after Dose 2
Reported as:
Geometric mean · Titer
GMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2
TiterBNT162b2Placebo
NT50: Baseline10.2 (9.8 to 10.6)10.0 (10.0 to 10.0)
NT50: 21 days after Dose 129.2 (24.3 to 35.2)10.0 (10.0 to 10.0)
NT50: 7 days after Dose 2408.2 (352.0 to 473.3)10.0 (10.0 to 10.0)
NT50: 14 days after Dose 2379.4 (335.3 to 429.3)10.0 (10.0 to 10.0)
NT50: 6 months after Dose 2145.6 (126.1 to 168.2)20.5 (20.5 to 20.5)
NT50: 12 months after Dose 274.2 (59.6 to 92.3)63.8 (0.5 to 8440.7)
NT90: Baseline10.1 (9.9 to 10.2)10.0 (10.0 to 10.0)
NT90: 21 days after Dose 111.4 (10.5 to 12.5)10.0 (10.0 to 10.0)
NT90: 7 days after Dose 2104.3 (90.1 to 120.7)10.0 (10.0 to 10.0)
NT90: 14 days after Dose 295.8 (84.8 to 108.2)10.0 (10.0 to 10.0)
SecondaryGMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2

GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFRs of SARS-CoV-2 NT50 and NT90 were reported in this outcome measure.

Time frame:
NT50: Before vaccination up to 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2
Reported as:
Geometric mean · Fold rise
GMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2
Fold riseBNT162b2Placebo
NT50: before vaccination up to 21 days after Dose 12.9 (2.4 to 3.4)1.0 (1.0 to 1.0)
NT50: before vaccination up to 7 days after Dose 240.1 (34.6 to 46.5)1.0 (1.0 to 1.0)
NT50: before vaccination up to 14 days after Dose 237.2 (32.9 to 42.1)1.0 (1.0 to 1.0)
NT50: before vaccination up to 6 months after Dose 214.3 (12.4 to 16.5)2.1 (2.1 to 2.1)
NT50: before vaccination up to 12 months after Dose 27.3 (5.9 to 9.1)6.4 (0.0 to 844.1)
NT90: before vaccination up to 21 days after Dose 11.1 (1.1 to 1.2)1.0 (1.0 to 1.0)
NT90: before vaccination up to 7 days after Dose 210.3 (8.9 to 12.0)1.0 (1.0 to 1.0)
NT90: before vaccination up to 14 days after Dose 29.5 (8.4 to 10.7)1.0 (1.0 to 1.0)
SecondaryGMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2

GMTs of SARS-CoV-2 neutralizing titers was planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution.

Time frame:
Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 1, 6 and 12 months after Dose 2

No measurements were reported for this outcome.

SecondaryGMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2

GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution).

Time frame:
Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2 and 1, 6 and 12 months after Dose 2

No measurements were reported for this outcome.

Adverse events

Collected over Local reactions/systemic events: within 7 days after each dose; SAEs: from Dose 1 up to 12 months after Dose 2 except for Placebo Then BNT162b2 reporting arm; SAEs for Placebo Then BNT162b2 reporting arm: from Dose 3 up to 6 months after Dose 4: other AEs: from Dose 1 up to 1 month after Dose 2 for BNT162b2 and Placebo arms; from Dose 3 up to 1 month after Dose 4 for Placebo Then BNT162b2 reporting arm.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BNT162b20/119 (0%)2/119 (1.7%)111/119 (93.3%)
Placebo0/41 (0%)0/41 (0%)12/41 (29.3%)
Placebo Then BNT162b20/35 (0%)0/35 (0%)31/35 (88.6%)
Most frequent serious events
Most frequent serious events
EventBNT162b2PlaceboPlacebo Then BNT162b2
PneumoniaInfections and infestations1/1190/410/35
Ovarian neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1190/410/35
Most frequent other events
Showing 10 of 27
Most frequent other events
EventBNT162b2PlaceboPlacebo Then BNT162b2
Injection site pain (PAIN)General disorders109/1191/410/35
Injection site painGeneral disorders0/1190/4131/35
Fatigue (FATIGUE)General disorders75/1194/410/35
FatigueGeneral disorders0/1190/4121/35
Headache (HEADACHE)Nervous system disorders64/1198/410/35
Chills (CHILLS)General disorders58/1193/410/35
HeadacheNervous system disorders2/1191/4117/35
PyrexiaGeneral disorders1/1191/4116/35
ArthralgiaMusculoskeletal and connective tissue disorders0/1190/4113/35
Pyrexia (FEVER)General disorders43/1190/410/35

Baseline characteristics

Safety population included all randomized participants who received at least 1 dose of the study intervention.

Age, Continuous
Age, Continuous(Years)BNT162b2PlaceboTotal
Mean46.8 ± 16.1644.8 ± 17.7646.3 ± 16.55
Age, Customized
Age, Customized(Participants)BNT162b2PlaceboTotal
20-64 Years9733130
65-85 Years22830
Sex: Female, Male
Sex: Female, Male(Participants)BNT162b2PlaceboTotal
Female601979
Male592281
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BNT162b2PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino11941160
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BNT162b2PlaceboTotal
American Indian or Alaska Native000
Asian11941160
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • SOUSEIKAI Sumida Hospital
    Sumida-ku, Tokyo 130-0004, Japan
  • SOUSEIKAI PS Clinic
    Fukuoka, 812-0025, Japan
09

References and documents

Publications

  • Haranaka M, Baber J, Ogama Y, Yamaji M, Aizawa M, Kogawara O, Scully I, Lagkadinou E, Tureci Ӧ, Sahin U, Dormitzer PR, Gruber WC, Lockhart S. A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nat Commun. 2021 Dec 14;12(1):7105. doi: 10.1038/s41467-021-27316-2. PubMed 34907170 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Nov 2021, 13 months.

Results were first posted in Feb 2023, 1 year 2 months after primary completion.

Of 44 industry-sponsored phase 4 interventional studies under COVID-19, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 13 months is above that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2020
First posted
Oct 19, 2020
StartActual
Oct 21, 2020
Primary completionActual
Nov 25, 2021
CompletionActual
Nov 25, 2021
Results first posted
Feb 1, 2023
Last update
Feb 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04588480
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Oct 21, 2020
Primary completion
Nov 25, 2021
Completion
Nov 25, 2021
Results posted
Feb 1, 2023
Last update
Feb 1, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion